Trial · NCT03352427
Adverse events29
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 29
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Muscle weakness lower limb | Musculoskeletal and connective tissue disorders | Dasatinib+Everolimus | 1 | 3 | |
| other | Eye disorders | Eye disorders | Dasatinib+Everolimus | 1 | 3 | |
| other | Dysarthria | Nervous system disorders | Dasatinib+Everolimus | 1 | 3 | |
| other | Myalgia | Musculoskeletal and connective tissue disorders | Dasatinib+Everolimus | 2 | 3 | |
| other | Fatigue | General disorders | Dasatinib+Everolimus | 1 | 3 | |
| other | Diarrhea | Gastrointestinal disorders | Dasatinib+Everolimus | 3 | 3 | |
| other | Ataxia | Nervous system disorders | Dasatinib+Everolimus | 1 | 3 | |
| other | Seizure | Nervous system disorders | Dasatinib+Everolimus | 1 | 3 | |
| other | Facial nerve disorder | Nervous system disorders | Dasatinib+Everolimus | 1 | 3 | |
| other | Hiccups | Respiratory, thoracic and mediastinal disorders | Dasatinib+Everolimus | 1 | 3 | |
| other | Vomitting | Gastrointestinal disorders | Dasatinib+Everolimus | 2 | 3 | |
| other | Rash maculo-papular | Skin and subcutaneous tissue disorders | Dasatinib+Everolimus | 2 | 3 | |
| other | Headache | Nervous system disorders | Dasatinib+Everolimus | 2 | 3 | |
| other | Rhinorrhea | Respiratory, thoracic and mediastinal disorders | Dasatinib+Everolimus | 1 | 3 | |
| other | Neck pain | Musculoskeletal and connective tissue disorders | Dasatinib+Everolimus | 1 | 3 | |
| other | Blurred vision | Eye disorders | Dasatinib+Everolimus | 1 | 3 | |
| other | Edema face | General disorders | Dasatinib+Everolimus | 1 | 3 | |
| other | Ear and labyrinth disorders - Other | Ear and labyrinth disorders | Dasatinib+Everolimus | 1 | 3 | |
| other | Hypophosphatemia | Metabolism and nutrition disorders | Dasatinib+Everolimus | 1 | 3 | |
| other | tremor | Nervous system disorders | Dasatinib+Everolimus | 1 | 3 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03352427/events